Hyperion Therapeutics to Present at the 26th Annual Roth Conference

Loading...
Loading...

BRISBANE, Calif., March 7, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics HPTX announced today that the company is scheduled to present at the 26th Annual Roth Conference on Tuesday, March 11, 2014 at 10:30 a.m. PT.

Jeffrey S. Farrow, chief financial officer, will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed internationally through business partners. For more information, please visit www.hyperiontx.com.

CONTACT: Myesha Edwards Assoc. Dir., Corporate Communications and Investor Relations (650) 745-7829
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...